Life
Beeline Medicine Launches with Ambitious Plans for Lupus Treatment
Beeline Medicine, a new biotech startup, is set to develop a series of drugs targeting inflammatory and immune disorders, beginning with a daily pill for lupus.
editorial-staff
1 min read
Updated about 11 hours ago
Summary
Beeline Medicine has emerged as a new player in the biotech sector, focusing on the development of five drugs aimed at treating inflammatory and immune disorders.
The startup plans to kick off its efforts with a daily pill designed for lupus, a chronic autoimmune disease.
Although the CEO has not been disclosed, the company builds on previous work involving Bristol-Myers Squibb drugs, indicating a strong foundation for its initiatives.
Updates
- No subsequent updates recorded.